Advanced Research Center Inc.

Summary

Advanced Research Center Inc. is a medical facility located in Anaheim, California. This center is recognized for care of Schizophrenia, Alzheimer's Disease, Major Depressive Disorder, Depression, Migraine and other specialties. Advanced Research Center Inc. is involved with conducting 125 clinical trials across 101 conditions. There are 6 research doctors associated with this hospital, such as Daniel Johnson, MD, Austina Cho, MD, Rennan Quijano, MD, and Johnson.

Top PIs

Clinical Trials running at Advanced Research Center Inc.

Alzheimer's Disease

Migraine

Bipolar disorder

Mania

Vestibular Migraine

Schizophrenia

Depression

COVID-19

Alzheimer's Dementia

Dementia

KarXT

for Alzheimer's-Related Psychosis

This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027, CN012-0056 or CN012-0034. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study, 14-week CN012-0056 or 14 week CN012-0034 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT and KarXT + KarX-EC in subjects with psychosis associated with Alzheimer's Disease.

Recruiting

2 awards

Phase 3

Buntanetap

for Alzheimer's Disease

The goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as measured by ADAS-Cog13? * Does buntanetap/Posiphen improve function as measured by ADCS-iADL? * What medical issues do participants have, if any, when taking buntanetap/Posiphen? Researchers will compare buntanetap/Posiphen to a placebo (a look-alike substance that contains no drug) to see if buntanetap/Posiphen works to treat early Alzheimer's disease. Participants will: * Take buntanetap/Posiphen or a placebo every day for 18 months * Visit the clinic periodically for checkups, tests, and questionnaires (screening visits, enrollment, month 1, month 3, month 6, month 9, month 12, month 15, month 18), including a volumetric MRI at month 6 and month 18 * Complete pre- and post-clinic visit phone calls

Recruiting

1 award

Phase 3

6 criteria

KarXT

for Psychosis in Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

Recruiting

1 award

Phase 3

1 criteria